

# Shuang Li

P: +31 6 33500987 | E: lishuang164224@outlook.com

LI: linkedin.com/in/shuang-li-43b35517b/



## SUMMARY

Highly motivated and detail-oriented scientist with expertise in **immunochemistry** and **ligand binding assays (ELISA)**. Proven experience in designing, validating, and executing high-quality immunoassays to support biologics development. Skilled in **data analysis**, **cross-functional collaboration**, and **mentoring junior staff**. Adept at troubleshooting, optimizing workflows, and ensuring compliance with scientific and ethical standards in a dynamic, fast-paced environment.

## EXPERIENCE

### Senior Technician | MERUS, The Netherlands | 2023.06 – Now

- Designed and conducted high-quality experiments to characterize bispecific antibody responses using **ELISA** and **flow cytometry**, ensuring robust and reproducible results.
- Developed and validated **cell-based assays** to evaluate antibody efficacy and mechanism of action, supporting biologics development.
- Drafted and updated **Standard Operating Procedures (SOPs)** and protocols, ensuring compliance with **scientific and ethical standards**.
- Collaborated with cross-functional teams to align project goals with organizational objectives, contributing to strategic decision-making.
- Presented experimental data and findings at project meetings, providing insights for the advancement of biologics development programs.

### Senior Analyst | University Medical Center Utrecht (UMCU), The Netherlands | 2022.04 – 2023.03

- Optimized mass spectrometry imaging (MALDI-MSI) protocols for tumor classification and biomarker discovery, ensuring high-quality data for scientific and regulatory purposes.
- Conducted detailed analysis of peptides, lipids, glycans, and metabolites in cancer tissues, contributing to the development of novel therapeutics.
- Maintained meticulous digital records of experiments, ensuring traceability and compliance with scientific standards.
- Collaborated with interdisciplinary teams to integrate scientific insights into project timelines.

### PhD Candidate | University Medical Center Utrecht (UMCU), The Netherlands | 2017 – 2022

- Led research projects focused on cancer immunotherapy, including the development of monoclonal antibody-based therapies.
- Published peer-reviewed manuscripts and presented findings at international conferences, demonstrating strong communication and presentation skills.
- Supervised and mentored junior researchers, fostering a culture of continuous learning and collaboration.
- Collaborated with cross-functional teams to design experiments and ensure adherence to scientific and ethical guidelines.

### Research Assistant, MSc | Institute of Translational Medicine, Jilin University, China | 2014 – 2017

- Conducted in vitro and in vivo experiments to study TLR-activated plasmacytoid dendritic cells and their role in inhibiting breast cancer cell growth.
- Developed expertise in **flow cytometry**, **cell isolation**, and **mouse models**, contributing to the development of novel immunotherapies.
- Published peer-reviewed manuscripts and presented findings at scientific conferences.

## EDUCATION

<b>UTRECHT UNIVERSITY – University Medical Center   The Netherlands</b> <b>PhD of Infection &amp; Immunity</b>	Oct 2017 – Jun 2022   4.5 yrs
<b>JILIN UNIVERSITY – Institute of Translational Medicine   China</b> <b>Master of Cell Biology</b>	Sep 2014 – Jun 2017   3 yrs
<b>JILIN UNIVERSITY – School of Pharmacy   China</b> <b>Bachelor of Medical Bioengineering</b>	Sep 2009 – Jun 2014   5 yrs

## SKILLS

- **Immunoassays:** ELISA, ligand binding assays, flow cytometry.
- **Bioanalytical Techniques:** Mass spectrometry imaging (MALDI-MSI), PCR, qPCR, Western blot, cell-based assays.
- **Data Analysis:** Proficient in data interpretation and visualization using software such as Prism, Excel, and FlowJo.
- **Languages:** English (Proficient), Chinese (Native), Dutch (A2)

## PUBLICATIONS

1. Li S, van Dijk CGM, Meeldijk J, Kok HM, Blommestein I, Verbakel ALF, Kotte M, Broekhuizen R, Laclé MM, Goldschmeding R, Cheng C, Bovenschen N. Extracellular Granzyme K Modulates Angiogenesis by Regulating Soluble VEGFR1 Release From Endothelial Cells. *Front Oncol.* 2021 Jun 9;11:681967. doi: 10.3389/fonc.2021.681967.
2. Li S, Poolen G, van Vliet L, Schipper J, Broekhuizen R, van Hecke W, Vermeulen J, Bovenschen N. Pediatric Medulloblastoma Express Immune Checkpoint B7-H3. *Clin Transl Oncol.* 2022 Jun;24(6):1204-1208. doi: 10.1007/s12094-021-02762-y.
3. Voskamp MJ<sup>†</sup>, Li S<sup>†</sup>, van Daalen KR, Crnko S, ten Broeke T, Bovenschen N. Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives. *Cancers.* 2021 Oct 27; 13(21):5387. doi: 10.3390/cancers13215387.
4. Li S, Wu J, Zhu S, Liu YJ, Chen J. Disease-Associated Plasmacytoid Dendritic Cells. *Front Immunol.* 2017 Oct 16;8:1268. doi: 10.3389/fimmu.2017.01268.

## KEY ACHIEVEMENTS

- Successfully designed and executed high-quality experiments for ADC characterization, contributing to the development of novel biologics with improved efficacy and reduced toxicity.
- Published multiple peer-reviewed articles on cancer immunotherapy, demonstrating expertise in monoclonal antibody research.
- Collaborated with cross-functional teams to integrate scientific insights into project timelines, ensuring alignment with organizational goals.
- Demonstrated strong soft skills, including communication, teamwork, and adaptability, in multicultural and multidisciplinary environments.